These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18220519)

  • 1. New approaches to the discovery of cdk5 inhibitors.
    Glicksman MA; Cuny GD; Liu M; Dobson B; Auerbach K; Stein RL; Kosik KS
    Curr Alzheimer Res; 2007 Dec; 4(5):547-9. PubMed ID: 18220519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.
    Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS
    Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.
    Ahn JS; Radhakrishnan ML; Mapelli M; Choi S; Tidor B; Cuny GD; Musacchio A; Yeh LA; Kosik KS
    Chem Biol; 2005 Jul; 12(7):811-23. PubMed ID: 16039528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
    Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.
    Corbel C; Zhang B; Le Parc A; Baratte B; Colas P; Couturier C; Kosik KS; Landrieu I; Le Tilly V; Bach S
    Chem Biol; 2015 Apr; 22(4):472-482. PubMed ID: 25865311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
    Hisanaga S; Saito T
    Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors.
    Corbel C; Wang Q; Bousserouel H; Hamdi A; Zhang B; Lozach O; Ferandin Y; Tan VB; Guéritte F; Colas P; Couturier C; Bach S
    Biotechnol J; 2011 Jul; 6(7):860-70. PubMed ID: 21681968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cyclin-dependent kinase 5 activators p35 and p39 interact with the alpha-subunit of Ca2+/calmodulin-dependent protein kinase II and alpha-actinin-1 in a calcium-dependent manner.
    Dhavan R; Greer PL; Morabito MA; Orlando LR; Tsai LH
    J Neurosci; 2002 Sep; 22(18):7879-91. PubMed ID: 12223541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.
    Liu M; Choi S; Cuny GD; Ding K; Dobson BC; Glicksman MA; Auerbach K; Stein RL
    Biochemistry; 2008 Aug; 47(32):8367-77. PubMed ID: 18636751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
    Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L
    Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an assay to screen for inhibitors of tau phosphorylation by cdk5.
    Ahn JS; Musacchio A; Mapelli M; Ni J; Scinto L; Stein R; Kosik KS; Yeh LA
    J Biomol Screen; 2004 Mar; 9(2):122-31. PubMed ID: 15006135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
    Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
    Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
    Maccioni RB; Otth C; Concha II; Muñoz JP
    Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract.
    Hosoi T; Uchiyama M; Okumura E; Saito T; Ishiguro K; Uchida T; Okuyama A; Kishimoto T; Hisanaga S
    J Biochem; 1995 Apr; 117(4):741-9. PubMed ID: 7592534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
    Zhong W; Liu H; Kaller MR; Henley C; Magal E; Nguyen T; Osslund TD; Powers D; Rzasa RM; Wang HL; Wang W; Xiong X; Zhang J; Norman MH
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5384-9. PubMed ID: 17709247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.
    Chou KC; Watenpaugh KD; Heinrikson RL
    Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
    Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
    Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.
    Li W; Allen ME; Rui Y; Ku L; Liu G; Bankston AN; Zheng JQ; Feng Y
    J Neurosci; 2016 Nov; 36(44):11283-11294. PubMed ID: 27807169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in silico approach for the discovery of CDK5/p25 interaction inhibitors.
    Zhang B; Corbel C; Guéritte F; Couturier C; Bach S; Tan VB
    Biotechnol J; 2011 Jul; 6(7):871-81. PubMed ID: 21681969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.